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Epidemiology should not be forgotten in osteoarthritis imagingWe read with interest the article by Hayashi et al. 20111. In their
review titled ‘Osteoarthritis year 2010 in review: imaging’, a major
focus of criticismwas the choice of magnetic resonance (MR) pulse
sequences for imaging of joints. Indeed, in their summary they
suggest that “the peer-review process of osteoarthritis (OA)
imaging in any journal should involve musculoskeletal radiologists
experienced in OA research to ensure the publication of papers
with scientiﬁcally sound contents”.
This is an interesting notion and, if valid, should it be extended
to imaging in all areas of rheumatology research? One may argue
that there are no speciﬁc complexities that relate to OA that would
not also be present in other diseases, such as rheumatoid or psori-
atic arthritis or even more broadly to musculoskeletal research.
Also, by extension, perhaps all biomarker work should be assessed
by a biochemist and all joint mechanics by a biomechanist?
We would argue that such an approach is narrow. It does not
take into account the issues that are critical in developing a diag-
nostic method. When a diagnostic method is developed, whether
it be an imaging or serum biomarker or a clinical test, the ﬁrst
step is to optimize the method and then to validate it. Optimizing
the method with MR imaging must take into account a number
of competing issues. It involves matching the image sequences
with the structure(s) being assessed. There are also the signiﬁcant
resource issues, since the true cost of MR is directly proportional
to scan time. This is a major issue, particularly for publically funded
studies. Thus a balance is required between the sequences used
(and thus imaging time and cost) and the structures to be assessed.
Then there is the issue of whether contrast agent should be used,
adding more serious risks to the participants (e.g., nephrogenic
ﬁbrosis). These issues are signiﬁcant in large community based
studies, yet the authors of the review have only focussed on the
imaging sequences.
Any method must then be validated. Simply having MR
sequences that “look” better according to an expert in the ﬁeld is
not enough. There are other aspects that need consideration.
What makes a method valid? Showing that a measure actually
measures the tissue of interest is important. For example, to vali-
date the use of MR derived cartilage volume measurement, the
volume of cartilage obtained from MR imaging has been compared
to that obtained by volume displacement of cartilage dissected
from anatomical specimens, as has been done by us2 and others3.
However, this is not possible for all joint structures. The reproduc-
ibility of the method is important to ensure high quality data and
consistency over time and between readers. The clinical validity
is important. Clinical validity incorporates whether the measure
predicts clinically important outcomes. For example, our methods
to assess cartilage volume4, cartilage defects5, bone marrow
lesions6 and subchondral bone cysts7, have all been shown to be1063-4584/$ – see front matter  2011 Osteoarthritis Research Society International. Pu
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joint replacement.
The area of MR imaging is very exciting. There is the issue of
developing newmethodologies to examine different aspects of joint
structures. Whilst these may provide improved tissue contrast or
capture a new facet of tissue quality, whether these methods are
reproducible andpredict clinical outcomes or structural progression
needs to be studied, thus validating these newmeasures. Indeed, in
a recent review on imaging in OA the authors of this current review
describe interesting new developments8. However when they
summarize these new developments, they point out that many
have not been shown to be clinically useful. In OA research, as
with any other area, there is a need for an objective, scientiﬁc,
assessment of the data. For example, if a ﬁnding in a study is based
on a less sensitive imaging method, this does not mean that this
result is invalid, but that if a more sensitive imaging method were
used, a smaller study population would have been required to
show the same effect. This is because using a less sensitive imaging
method is likely to result in non-differential misclassiﬁcationwhich
will tend to underestimate any effects being examined.
We agree with the authors that the peer-review process of OA
imaging in any journal needs to ensure the publication of papers
with scientiﬁcally sound content. However we would argue that
this needs to be objective and based on sound scientiﬁc and epide-
miological principles. We suggest that the cause of OA research will
be better served by having work reviewed by individuals with
a comprehensive understanding of the issues around diagnostic
methodology.Whilst thismay involvemusculoskeletal radiologists,
but there is little evidence that it should be restricted to this
specialty group. Indeed, the extensive, high quality imaging
research performed over the last 50 years in OA, suggests this
does not need to be the case.
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